Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects
Round 1
Reviewer 1 Report
The review of Waliszewska-Prosół et al. is concise and well written.
In the introduction it was explained the clinical and immunological differences between MOG associated diseases and AQP4 positive NMOSD.
The article provides an updated overview of current and future treatment options for NMO patients.
I recommend the paper be accepted for publication in its current form.
Author Response
Authors' response to the Reviewer comments
Dear Reviewer,
Thank you very much for your review. English language and style was check by native speaker.
Hopefully, the revised version of the manuscript, considering the above issues, would be found suitable for publication.
Authors
Reviewer 2 Report
Thank you for this nice and comprehensive review.
The last part on future directions is very informative.
The more recent trial of eculizumab should be added though.
Author Response
Authors' response to the Reviewer comments
Dear Reviewer,
Thank you very much for your comprehensive remark and suggestion. Changes have been made in the current version of the manuscript in yellow. We corrected the manuscript according to your proposal.
We've added more information about eculizumab (section 4.2.4 in manuscript) and added five new references (72-76).
English language and style was check by native speaker.
Hopefully, the revised version of the manuscript, considering the above issues, would be found suitable for publication.
Authors